Results from a phase II trial of a combination of lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) which was not responding to treatment with immune checkpoint inhibitor therapy was presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend.
One hundred and four (104) patients with metastatic RCC and who were no longer responding to treatment with immune checkpoint inhibitor therapy were included in the study. All patients were treated with the combination of lenvatinib and pembrolizumab. The objective response rate was 51%, progression-free survival was 11.7 months, and median duration of response was 9.9 months.
This study provided some very strong and encouraging data on the lenvatinib plus pembrolizumab combination as a second-line option for patients with metastatic RCC who have progressed on immunotherapy. The study also supports further development of this combination as a later-line therapy in advanced RCC.